Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 26;13(23):5945.
doi: 10.3390/cancers13235945.

Radiotherapy in Medulloblastoma-Evolution of Treatment, Current Concepts and Future Perspectives

Clemens Seidel  1 , Sina Heider  1 , Peter Hau  2 , Annegret Glasow  1 , Stefan Dietzsch  1 , Rolf-Dieter Kortmann  1
Affiliations
Review

Radiotherapy in Medulloblastoma-Evolution of Treatment, Current Concepts and Future Perspectives

Clemens Seidel et al. Cancers (Basel). .

Abstract

Medulloblastoma is the most frequent malignant brain tumor in children. During the last decades, the therapeutic landscape has changed significantly with craniospinal irradiation as the backbone of treatment. Survival times have increased and treatments were stratified according to clinical and later molecular risk factors. In this review, current evidence regarding the efficacy and toxicity of radiotherapy in medulloblastoma is summarized and discussed mainly based on data of controlled trials. Current concepts and future perspectives based on current risk classification are outlined. With the introduction of CSI, medulloblastoma has become a curable disease. Due to combination with chemotherapy, survival rates have increased significantly, allowing for a reduction in radiation dose and a decrease of toxicity in low- and standard-risk patients. Furthermore, modern radiotherapy techniques are able to avoid side effects in a fragile patient population. However, high-risk patients remain with relevant mortality and many patients still suffer from treatment related toxicity. Treatment needs to be continually refined with regard to more efficacious combinatorial treatment in the future.

Keywords: craniospinal irradiation; medulloblastoma; neurotoxicity; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Smoll N.R., Drummond K.J. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J. Clin. Neurosci. 2012;19:1541–1544. doi: 10.1016/j.jocn.2012.04.009. - DOI - PubMed
    1. Packer R.J., Gajjar A., Vezina G., Rorke-Adams L., Burger P.C., Robertson P.L., Bayer L., LaFond D., Donahue B.R., Marymont M.H., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol. 2006;24:4202–4208. doi: 10.1200/JCO.2006.06.4980. - DOI - PubMed
    1. Taylor R.E., Bailey C.C., Robinson K.J., Weston C.L., Walker D.A., Ellison D., Ironside J., Pizer B.L., Lashford L.S. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur. J. Cancer. 2005;41:727–734. doi: 10.1016/j.ejca.2004.12.017. - DOI - PubMed
    1. Michalski J.M., Janss A.J., Vezina L.G., Smith K.S., Billups C.A., Burger P.C., Embry L.M., Cullen P.L., Hardy K.K., Pomeroy S.L., et al. Children’s Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. J. Clin. Oncol. 2021;39:2685–2697. doi: 10.1200/JCO.20.02730. - DOI - PMC - PubMed
    1. Bloom H.J., Wallace E.N., HENK J.M. The treatment and prognosis of medulloblastoma in children. A study of 82 verified cases. Am. J. Roentgenol. Radium Ther. Nucl. Med. 1969;105:43–62. doi: 10.2214/ajr.105.1.43. - DOI - PubMed

LinkOut - more resources